Taking Multivitamins/Minerals Doesn't Improve CVD Outcomes
WEDNESDAY, July 11, 2018 -- Multivitamin/mineral (MVM) supplementation seems not to be associated with cardiovascular disease (CVD) outcomes, according to a review published online July 10 in Circulation: Cardiovascular Quality and Outcomes.
Joonseok Kim, M.D., from the University of Alabama at Birmingham, and colleagues conducted a comprehensive literature review to examine the correlation between MVM supplementation and CVD outcomes including coronary heart disease (CHD) and stroke. Data from 18 studies with 2,019,862 participants and 18,363,326 person-years of follow-up were included in the analysis.
The researchers found that there was no correlation between MVM supplementation and CVD mortality, CHD mortality, stroke mortality, or stoke incidence (relative risks, 1 [95 percent confidence interval, 0.97 to 1.04], 1.02 [95 percent confidence interval, 0.92 to 1.13], 0.95 [95 percent confidence interval, 0.82 to 1.09], and 0.98 [95 percent confidence interval, 0.91 to 1.05]). In prespecified subgroups, and after adjustment for diet, smoking, physical activity, and study site, there was no correlation between MVM supplements and CVD or CHD mortality. MVM use was associated with reduced risk of CHD incidence (relative risk, 0.88; 95 percent confidence interval, 0.79 to 0.97); in pooled subgroup analysis of randomized controlled trials, this correlation did not remain significant (relative risk, 0.97; 95 percent confidence interval, 0.8 to 1.19).
"Our meta-analysis of clinical trials and prospective cohort studies demonstrates that MVM supplementation does not improve cardiovascular outcomes in the general population," the authors write.
© 2020 HealthDay. All rights reserved.
Posted: July 2018
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.